

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 June 2023 (15.06.2023)



(10) International Publication Number
WO 2023/108082 A1

(51) International Patent Classification:

A61K 31/33 (2006.01) A61K 31/416 (2006.01)
A61K 31/343 (2006.01) A61K 31/4162 (2006.01)

(21) International Application Number:

PCT/US2022/081197

(22) International Filing Date:

08 December 2022 (08.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/287,872 09 December 2021 (09.12.2021) US

(71) Applicants: **MATERIA THERAPEUTICS INC.**

[US/US]; 3750 Las Vegas Blvd S., Unit #3004, Las Vegas, Nevada 89158 (US). **UNIVERSITY OF CYPRUS** [CY/CY]; Council-Senate Building, Anastasios G. Leventis; 1 University Avenue, Aglantzia, Nicosia, 2109 (CY).

(72) Inventors: **MARTIN, John D.**; c/o University of

Cyprus; Council-Senate Building, Anastasios G. Leventis; 1 University Avenue, Aglantzia, Nicosia, 2109 (CY). **STYLIANOPOULOS, Triantafyllos**; Ioanni Stylianou 3A, Apt. 301, Strovolos, Nicosia, 2003 (CY). **MPEKRIS, Fotios**; c/o University of Cyprus; Council-Senate Building, Anastasios G. Leventis; 1 University Avenue, Aglantzia, Nicosia, 2109 (CY). **PANAGI, Myrofora**; c/o University of Cyprus; Council-Senate Building, Anastasios G. Leventis; 1 University Avenue, Aglantzia, Nicosia, 2109 (CY). **VOUTOURI, Chrysovalantis**; c/o University of Cyprus; Council-Senate Building, Anastasios G. Leventis; 1 University Avenue, Aglantzia, Nicosia, 2109 (CY).

(74) Agent: **FRAUSTO, Stephen** et al.; Morrison & Foerster

LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: CANCER TREATMENT USING KETOTIFEN IN COMBINATION WITH A CHECKPOINT INHIBITOR

(57) Abstract: The present invention is directed to a combination treatment using ketotifen and a checkpoint inhibitor that is effective in treating cancer or inhibiting the proliferation of tumor cells in a subject and/or that can initiate, enhance or prolong the immune response to tumor cells.

WO 2023/108082 A1